

소개
In recent years, the European Union (EU) has witnessed recurrent disruptions in the pharmaceutical supply chain, highlighting the urgent need for robust policies that guarantee access to critical medicines. While these shortages are detrimental to the general patient population, they pose a particularly severe threat to the rare disease community, whose treatments often rely on niche manufacturing processes with limited production capacity.



